Fundamental Analysis of INMUNE BIO INC(NASDAQ:INMB) stock

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to INMB. INMB was compared to 588 industry peers in the Biotechnology industry. While INMB has a great health rating, there are worries on its profitability. While showing a medium growth rate, INMB is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year INMB has reported negative net income.

INMB had a negative operating cash flow in the past year.

INMB had negative earnings in each of the past 5 years.

In the past 5 years INMB always reported negative operating cash flow.

1.2 Ratios

INMB has a Return On Assets (-52.64%) which is comparable to the rest of the industry.

INMB has a Return On Equity (-78.68%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-52.64%
ROE	-78.68%
ROIC	N/A

ROA(3y)-38.79%

ROA(5y)-35.5%

ROE(3y)-53.97%

ROE(5y)-45.14%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

INMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

INMB does not have a ROIC to compare to the WACC, probably because it is not profitable.

INMB has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for INMB has been increased compared to 5 years ago.

INMB has a better debt/assets ratio than last year.

2.2 Solvency

INMB has an Altman-Z score of 2.24. This is not the best score and indicates that INMB is in the grey zone with still only limited risk for bankruptcy at the moment.

The Altman-Z score of INMB (2.24) is better than 71.75% of its industry peers.

There is no outstanding debt for INMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	2.24

ROIC/WACCN/A

WACC9.18%

2.3 Liquidity

INMB has a Current Ratio of 2.16. This indicates that INMB is financially healthy and has no problem in meeting its short term obligations.

INMB's Current ratio of 2.16 is on the low side compared to the rest of the industry. INMB is outperformed by 75.86% of its industry peers.

A Quick Ratio of 2.16 indicates that INMB has no problem at all paying its short term obligations.

The Quick ratio of INMB (2.16) is worse than 74.32% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.16
Quick Ratio	2.16

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for INMB have decreased by -9.87% in the last year.

INMB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -58.42%.

The Revenue has been growing by 149.33% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-9.87%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-46.87%

Revenue 1Y (TTM)-58.42%

Revenue growth 3Y149.33%

Revenue growth 5YN/A

Revenue growth Q2Q-72%

3.2 Future

Based on estimates for the next years, INMB will show a very strong growth in Earnings Per Share. The EPS will grow by 36.31% on average per year.

Based on estimates for the next years, INMB will show a very strong growth in Revenue. The Revenue will grow by 312.45% on average per year.

EPS Next Y-33.96%

EPS Next 2Y-9.27%

EPS Next 3Y-4.44%

EPS Next 5Y36.31%

Revenue Next Year-16.87%

Revenue Next 2Y-4.77%

Revenue Next 3Y-3.21%

Revenue Next 5Y312.45%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INMB. In the last year negative earnings were reported.

Also next year INMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as INMB's earnings are expected to decrease with -4.44% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-9.27%

EPS Next 3Y-4.44%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for INMB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INMUNE BIO INC

NASDAQ:INMB (4/26/2024, 7:00:02 PM)

11.29

+0.45 (+4.15%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap203.56M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-52.64%
ROE	-78.68%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.16
Quick Ratio	2.16
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-9.87%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-33.96%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-58.42%

Revenue growth 3Y149.33%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

INMUNE BIO INC (INMB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens